logo
logo
NVST stock ticker logo

Envista Holdings Corporation

NYSE•NVST
CEO: Mr. Stephen Keller
セクター: Healthcare
業種: Medical - Equipment & Services
上場日: 2019-09-18
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
連絡先情報
Building E, 200 South Kraemer Boulevard, Brea, CA, 92821-6208, United States
714-817-7000
envistaco.com
時価総額
$4.05B
PER (TTM)
86.1
54.9
配当利回り
--
52週高値
$30.42
52週安値
$14.22
52週レンジ
64%
順位40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
9年ファンダメンタル
堅調 • 4.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2017-2025

財務ダッシュボード

Q4 2025 データ

売上高

$750.60M+0.00%
直近4四半期の推移

EPS

$0.20+0.00%
直近4四半期の推移

フリーCF

$91.70M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Total sales reached $2.72B USD in 2025, reflecting a strong 8.3% GAAP growth compared to the prior year.
Profitability Rebound Net income was $47.0M USD, successfully reversing the substantial $1.12B net loss recorded in 2024 operations.
Impairment Absence Zero goodwill impairment recorded in 2025 versus $1.15B goodwill and intangible asset charge recognized in 2024.
Core Sales Strength Core sales grew 6.5% USD, driven by Specialty Products segment achieving 6.3% growth for the fiscal year.

リスク要因

Global Economic Volatility Global economy, inflation, and interest rates may adversely affect customer demand and utilization rates across served markets.
Trade Policy Uncertainty Trade disputes, tariffs, and protectionism increase sourcing costs and restrict market access across international operations.
Cybersecurity Incident Risk IT system breaches or ransomware attacks could seriously harm operations, cause data loss, and result in reputational damage.
Distributor Concentration Loss of key distributor Henry Schein, accounting for 12% of 2025 sales, poses a material concentration risk to revenue streams.

見通し

Strategic Growth Investment Investing in innovation, commercialization, and clinical education remains a key priority to accelerate overall business growth trajectory.
Emerging Market Focus Continue investing in emerging markets, which represented 22% of 2025 total sales volume, expecting strong future growth driver.
Operational Efficiency Focus Utilizing Envista Business System (EBS) to improve manufacturing performance and streamline overall operational cost structure.
Recent Acquisition Integration Completed Versah acquisition for approximately $55.0M cash in February 2026 to expand portfolio with innovative dental technology.

同業比較

売上高 (TTM)

ALHC stock ticker logoALHC
$3.95B
+46.1%
XRAY stock ticker logoXRAY
$3.68B
-3.0%
NVST stock ticker logoNVST
$2.72B
+8.3%

粗利益率 (最新四半期)

SUPN stock ticker logoSUPN
89.1%
-15.2pp
RARE stock ticker logoRARE
86.0%
-2.4pp
INDV stock ticker logoINDV
82.1%
-4.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CGON$5.43B-30.9-22.9%0.9%
TMDX$4.24B22.253.9%44.0%
NVST$4.05B86.11.5%30.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.8%
安定成長
4四半期純利益CAGR
22.3%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし